Timothy P. Walbert
Director, Board of Directors
Mr. Walbert became a Director of Sucampo in October 2015. He currently serves as President and Chief Executive Officer and Chairman of the Board of Directors of Horizon Pharma plc. Prior to Horizon Pharma, he served as President, Chief Executive Officer and Director of IDM Pharma, Inc. from May 2007 until the acquisition of IDM by Takeda in June 2009, and as Executive Vice President, Commercial Operations of NeoPharm, Inc. from 2006 to 2007. From 2001 to 2005, Mr. Walbert was the Divisional Vice President and General Manager, Immunology, and Divisional Vice President, Global Cardiovascular Strategy at Abbott, now AbbVie, where he led the global development and launch of the multi-indication biologic HUMIRA. Earlier in his career, he held the position of Director, Celebrex North America and Arthritis Team Leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company, now Pfizer, as well as sales and marketing roles with increasingly responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth Pharmaceuticals, Inc., now Pfizer.
Mr. Walbert is currently chairman of Egalet Corporation and the Illinois Biotechnology Industry Organization (iBIO). Mr. Walbert is a member of the Board of Directors of XOMA Corporation, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC), the Greater Chicago Arthritis Foundation and the Illinois Innovation Council.
Mr. Walbert earned a bachelor’s degree from Muhlenberg College.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.